Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Gynecol Oncol. 2023 Nov 17;179:115–122. doi: 10.1016/j.ygyno.2023.10.017

Figure 2:

Figure 2:

Nonrandomized comparison of progression-free survival (PFS) among Gynecologic Oncology Group (GOG) studies using cytotoxic single-agent compounds (GOG 127B-K) and bevacizumab (GOG 227C) in recurrent metastatic cervical cancer.

PF: progression free

Reprinted from Journal of Clinical Oncology, Volume 27, Issue 7, Monk BJ, Sill MW, Burger RA, et al., Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, Pages 1069–1074, Copyright (2009). Reprinted with permission from Wolters Kluwer Health, Inc.